Log in

Brainsway Stock Forecast, Price & News

-0.16 (-2.58 %)
(As of 10/26/2020 12:00 AM ET)
Today's Range
Now: $6.04
50-Day Range
MA: $5.99
52-Week Range
Now: $6.04
Volume8,158 shs
Average Volume9,346 shs
Market Capitalization$65.36 million
P/E RatioN/A
Dividend YieldN/A
Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:BWAY



Sales & Book Value

Annual Sales$23.10 million
Book Value$2.24 per share


Net Income$-10,330,000.00


Market Cap$65.36 million
Next Earnings Date11/23/2020 (Estimated)
OptionableNot Optionable
-0.16 (-2.58 %)
(As of 10/26/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BWAY News and Ratings via Email

Sign-up to receive the latest news and ratings for BWAY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Brainsway (NASDAQ:BWAY) Frequently Asked Questions

How has Brainsway's stock price been impacted by COVID-19?

Brainsway's stock was trading at $8.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BWAY stock has decreased by 26.2% and is now trading at $6.0410.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Brainsway?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainsway in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Brainsway

When is Brainsway's next earnings date?

Brainsway is scheduled to release its next quarterly earnings announcement on Monday, November 23rd 2020.
View our earnings forecast for Brainsway

How were Brainsway's earnings last quarter?

Brainsway Ltd. (NASDAQ:BWAY) posted its earnings results on Wednesday, August, 12th. The company reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.09. The business earned $4.82 million during the quarter, compared to the consensus estimate of $4.70 million. Brainsway had a negative net margin of 42.27% and a negative return on equity of 38.87%.
View Brainsway's earnings history

What price target have analysts set for BWAY?

3 Wall Street analysts have issued 12 month price objectives for Brainsway's stock. Their forecasts range from $9.00 to $13.00. On average, they expect Brainsway's stock price to reach $11.67 in the next year. This suggests a possible upside of 93.1% from the stock's current price.
View analysts' price targets for Brainsway

Are investors shorting Brainsway?

Brainsway saw a increase in short interest in September. As of September 15th, there was short interest totaling 31,200 shares, an increase of 34.5% from the August 31st total of 23,200 shares. Based on an average daily volume of 24,000 shares, the short-interest ratio is currently 1.3 days.
View Brainsway's Short Interest

Who are some of Brainsway's key competitors?

What other stocks do shareholders of Brainsway own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Brainsway investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Pfizer (PFE), Neuronetics (STIM), Boingo Wireless (WIFI), Ampio Pharmaceuticals (AMPE), Eastman Chemical (EMN), Enbridge (ENB) and Energy Transfer (ET).

Who are Brainsway's key executives?

Brainsway's management team includes the following people:
  • Mr. Hadar Levy, Sr. VP & GM of North America (Age 46, Pay $409k)
  • Ms. Moria Ankri, VP R&D (Age 35, Pay $176k)
  • Dr. David Zacut, Founder & Chairman (Age 67)
  • Dr. Christopher R. von Jako Ph.D., Pres & CEO
  • Mr. Avner Hagai, Founder & Independent Vice-Chairman (Age 64)

When did Brainsway IPO?

(BWAY) raised $30 million in an IPO on Wednesday, April 17th 2019. The company issued 2,500,000 shares at a price of $11.94 per share. Cantor acted as the underwriter for the IPO.

What is Brainsway's stock symbol?

Brainsway trades on the NASDAQ under the ticker symbol "BWAY."

How do I buy shares of Brainsway?

Shares of BWAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Brainsway's stock price today?

One share of BWAY stock can currently be purchased for approximately $6.04.

How big of a company is Brainsway?

Brainsway has a market capitalization of $65.36 million and generates $23.10 million in revenue each year. The company earns $-10,330,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Brainsway employs 107 workers across the globe.

What is Brainsway's official website?

The official website for Brainsway is www.brainsway.com.

How can I contact Brainsway?

Brainsway's mailing address is 19 HARTUM STREET BYNET BUILDING 3RD FL Har HaHotzvim, Jerusalem L3, 9777518. The company can be reached via phone at 972-2581-3140 or via email at [email protected]

This page was last updated on 10/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.